{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:35:50Z","timestamp":1792103750745,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J01944"],"award-info":[{"award-number":["2020J01944"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J01703"],"award-info":[{"award-number":["2021J01703"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.yexcr.2022.113362","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T08:01:54Z","timestamp":1663747314000},"page":"113362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer"],"prefix":"10.1016","volume":"421","author":[{"given":"Kunlin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqin","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunwang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.yexcr.2022.113362_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/bcr2574","article-title":"Triple-negative breast cancer","volume":"12","author":"Chacon","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113362_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.breast.2010.03.026","article-title":"Management of triple negative breast cancer","volume":"19","author":"Oakman","year":"2010","journal-title":"Breast"},{"key":"10.1016\/j.yexcr.2022.113362_bib3","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2022.113362_bib4","first-page":"299","article-title":"Histone deacetylases as New therapeutic targets in triple-negative breast cancer: progress and promises","volume":"14","author":"Garmpis","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.yexcr.2022.113362_bib5","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.yexcr.2022.113362_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.18632\/oncoscience.412","article-title":"Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model","volume":"5","author":"Matossian","year":"2018","journal-title":"Oncoscience"},{"key":"10.1016\/j.yexcr.2022.113362_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/1535-7163.MCT-11-0979","article-title":"Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells","volume":"11","author":"Rao","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2022.113362_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00228-015-1967-z","article-title":"Panobinostat PK\/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory multiple myeloma","volume":"72","author":"Mu","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.yexcr.2022.113362_bib9","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2022.113362_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5896786","article-title":"New insights into the role of exercise in inhibiting mTOR signaling in triple-negative breast cancer","volume":"2018","author":"Agostini","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.yexcr.2022.113362_bib11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4161\/cbt.5.9.3175","article-title":"Therapeutic targets: MTOR and related pathways","volume":"5","author":"Dancey","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.yexcr.2022.113362_bib12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1535-7163.MCT-09-0763","article-title":"Dual inhibition of akt\/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma","volume":"9","author":"Cirstea","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2022.113362_bib13","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1158\/1078-0432.CCR-12-3110","article-title":"Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial","volume":"19","author":"Gonzalez-Angulo","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113362_bib14","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/0008-5472.CAN-12-1345","article-title":"Tumor cells upregulate normoxic HIF-1alpha in response to doxorubicin","volume":"73","author":"Cao","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113362_bib15","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1016\/j.biomaterials.2014.03.036","article-title":"Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin alpha3 in triple-negative breast cancer","volume":"35","author":"Dai","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.yexcr.2022.113362_bib16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1535-7163.MCT-10-0925","article-title":"Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells","volume":"10","author":"Liu","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2022.113362_bib17","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3192","article-title":"Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat","volume":"14","author":"Tate","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113362_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-010-1055-0","article-title":"Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73","volume":"128","author":"Su","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.yexcr.2022.113362_bib19","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1172\/JCI129049","article-title":"HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models","volume":"130","author":"Nguyen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yexcr.2022.113362_bib20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3892\/or.2017.5849","article-title":"Combination of rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude mice through autophagy\/p62\/Nrf2 pathway","volume":"38","author":"Li","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.yexcr.2022.113362_bib21","article-title":"Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells","volume":"16","author":"Huang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2022.113362_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbcan.2016.12.002","article-title":"Endoplasmic reticulum-mediated unfolded protein response and mitochondrial apoptosis in cancer","volume":"1867","author":"Bhat","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Canc."},{"key":"10.1016\/j.yexcr.2022.113362_bib23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12885-020-07070-2","article-title":"Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer","volume":"20","author":"Song","year":"2020","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.yexcr.2022.113362_bib24","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.breast.2017.06.023","article-title":"Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)","volume":"34","author":"Wein","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.yexcr.2022.113362_bib25","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.18632\/oncotarget.1314","article-title":"Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer","volume":"4","author":"Ellis","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2022.113362_bib26","doi-asserted-by":"crossref","first-page":"60169","DOI":"10.18632\/oncotarget.11109","article-title":"Superior efficacy of co-treatment with the dual PI3K\/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC","volume":"7","author":"Piao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2022.113362_bib27","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2022.113362_bib28","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.18632\/oncotarget.724","article-title":"Superior efficacy of co-treatment with dual PI3K\/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer","volume":"3","author":"Venkannagari","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2022.113362_bib29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2020.00256","article-title":"Mitochondrial redox hubs as promising targets for anticancer therapy","volume":"10","author":"Ippolito","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexcr.2022.113362_bib30","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1038\/s41598-021-84852-z","article-title":"Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer","volume":"11","author":"Dadali","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2022.113362_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105734","article-title":"Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance","volume":"122","author":"Mosleh","year":"2020","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.yexcr.2022.113362_bib32","first-page":"2028","article-title":"Dexamethasone-induced production of reactive oxygen species promotes apoptosis via endoplasmic reticulum stress and autophagy in MC3T3-E1 cells","volume":"41","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.yexcr.2022.113362_bib33","doi-asserted-by":"crossref","first-page":"13083","DOI":"10.1002\/jcp.27979","article-title":"Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation","volume":"234","author":"Whang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2022.113362_bib34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3892\/ol.2021.12596","article-title":"Miconazole induces autophagic death in glioblastoma cells via reactive oxygen species-mediated endoplasmic reticulum stress","volume":"21","author":"Jung","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.yexcr.2022.113362_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The unfolded protein response and cell fate control","volume":"69","author":"Hetz","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.yexcr.2022.113362_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3906\/biy-2010-62","article-title":"Endoplasmic reticulum stress and oncomir-associated chemotherapeutic drug resistance mechanisms in breast cancer tumors","volume":"45","author":"Mehdizadehtapeh","year":"2021","journal-title":"Turk. J. Biol."},{"key":"10.1016\/j.yexcr.2022.113362_bib37","article-title":"Neuroprotective effects of exercise postconditioning after stroke via SIRT1-mediated suppression of endoplasmic reticulum (ER) stress","volume":"15","author":"Li","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.yexcr.2022.113362_bib38","first-page":"12887","article-title":"Inhibition of CACNA1H can alleviate endoplasmic reticulum stress and reduce myocardial cell apoptosis caused by myocardial infarction","volume":"24","author":"Wang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.yexcr.2022.113362_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153399","article-title":"Effect of pristimerin on apoptosis through activation of ROS\/endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer","volume":"80","author":"Zhao","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.yexcr.2022.113362_bib40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.bbrc.2020.10.052","article-title":"ACP-5862 suppresses esophageal squamous cell carcinoma growth through inducing apoptosis via activation of endoplasmic reticulum stress and ROS production","volume":"534","author":"Liu","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2022.113362_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1593\/tlo.12271","article-title":"Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells","volume":"6","author":"Montalbano","year":"2013","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.yexcr.2022.113362_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2490-14-71","article-title":"Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells","volume":"14","author":"Sato","year":"2014","journal-title":"BMC Urol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448272200355X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448272200355X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:04Z","timestamp":1762147264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448272200355X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S001448272200355X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2022.113362","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2022.113362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113362"}}